{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:45:42Z","timestamp":1787244342791,"version":"build-2736575974"},"reference-count":14,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.3892\/ol.2015.3671","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T02:57:50Z","timestamp":1441249070000},"page":"2895-2898","source":"Crossref","is-referenced-by-count":10,"title":["Uncommon gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: A report of four cases"],"prefix":"10.3892","volume":"10","author":[{"given":"SHINTARO","family":"FUJIHARA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROHITO","family":"MORI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIDEKI","family":"KOBARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NORIKO","family":"NISHIYAMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAKI","family":"AYAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RYO","family":"OHATA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NOBUFUMI","family":"UEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIKIO","family":"SUGIMOTO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIYUKI","family":"KAKEHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TSUTOMU","family":"MASAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"key":"key20180108100615_b1-ol-0-0-3671","year":"2013","journal-title":"International Agency for Research on Cancer: The GLOBOCAN project: cancer incidence and mortality worldwide in"},{"key":"key20180108100615_b2-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"key20180108100615_b3-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"key20180108100615_b4-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted therapies for renal cell carcinoma: review of adverse event management strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"key20180108100615_b5-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.2008.19.9836","article-title":"Metastatic renal cell carcinoma: Many treatment options, one patient","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108100615_b6-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108100615_b7-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180108100615_b8-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","article-title":"The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis","volume":"48","author":"Gomez-Fernandez","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180108100615_b9-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1471-2369-14-141","article-title":"Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: A case report","volume":"14","author":"Fujihara","year":"2013","journal-title":"BMC Nephrol"},{"key":"key20180108100615_b10-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108100615_b11-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180108100615_b12-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"key20180108100615_b13-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol Cell Biol"},{"key":"key20180108100615_b14-ol-0-0-3671","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1464-410X.2010.09985.x","article-title":"Adverse events from targeted therapies in advanced renal cell carcinoma: The impact on long-term use","volume":"107","author":"Kirkali","year":"2011","journal-title":"BJU Int"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3671\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T07:31:13Z","timestamp":1515396673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,9,3]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.3892\/ol.2015.3671"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3671","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,3]]}}}